CHEMED director receives stock award
DeLyons Ron reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
DeLyons Ron reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Ron DeLyons received an award of 386 shares of Capital Stock on May 18, 2026. The shares were valued at $440.77 per share for the transaction. This was a grant or award, not an open-market purchase, and increased his direct holdings to 2,052 shares after the transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Capital Stock | 386 | $440.77 | $170K |
Footnotes (1)
- F1. Award of stock
Key Figures
Key Terms
Capital Stock financial
Grant, award, or other acquisition financial
direct ownership financial
Award of stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CHEMED CORP (CHE) director Ron DeLyons report?
At what price was the CHEMED CORP (CHE) stock award to Ron DeLyons valued?
What does transaction code A mean in the CHEMED CORP (CHE) Form 4 filing?
Is the CHEMED CORP (CHE) insider transaction by Ron DeLyons a buy or a grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.